Moonshot Launches Kimi K3, China's Largest Open-Source AI Model 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Nationwide Data Center Protests Highlight Growing Backlash Against AI Expansion 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Foxconn Wins First SpaceX AI Server Contract Worth Estimated $52 Billion 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
RFK Jr. Spokesman Resigns Over Trump Administration’s Flavored E-Cigarette Policy 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
KKR, AEW Seek China Property Sales as Commercial Real Estate Slump Deepens 
CDC Monitors 41 Americans After Andes Hantavirus Outbreak on Luxury Cruise Ship 
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Eli Lilly has announced that the U.S. Food and Drug Administration (FDA) has approved its new therapy, Inluriyo, for the treatment of advanced or metastatic breast cancer in adult patients who have already undergone prior therapy. This milestone approval marks a significant advancement in addressing a challenging form of cancer that often resists standard treatments.
Metastatic breast cancer, also known as Stage IV breast cancer, occurs when cancer spreads beyond the breast and nearby lymph nodes to other organs such as the bones, liver, lungs, or brain. Certain breast cancers develop ESR1 mutations, which cause estrogen receptors to become overly active. While these receptors normally regulate cell growth, their mutation can accelerate cancer progression. Inluriyo directly targets these receptors by binding to and breaking them down, effectively blocking their activity to help slow disease progression.
The FDA’s decision was based on data from a late-stage clinical trial showing that patients treated with Inluriyo had a 38% lower risk of disease progression or death compared to those receiving standard therapies. On average, patients taking Inluriyo went 5.5 months without cancer worsening, versus 3.8 months with other treatments.
Inluriyo is an oral therapy recommended at a daily dose of 400 mg—taken as two 200 mg tablets on an empty stomach. The drug will be available in the U.S. within weeks at a list price of $22,500 per 28-day cycle. Eli Lilly highlighted that the medication carries an embryo-fetal toxicity warning, underscoring the risks of exposure during pregnancy.
The company is also investigating Inluriyo in combination with abemaciclib, another Lilly therapy, for advanced breast cancer, as well as in early-stage disease as adjuvant treatment.
With its approval, Inluriyo offers patients with metastatic breast cancer and ESR1 mutations a new, targeted treatment option that could improve outcomes and provide hope in one of the toughest stages of breast cancer.
